Shahin Gharakhanian MD 1H2021 COVID-19 Activities’ PROGRESS REPORT

* Utay, N. S., Asmuth, D. M, Gharakhanian, S., Contreras, M., Warner, C. D., & Detzel, C. J. (2021). Potential use of serum-derived bovine immunoglobulin/protein isolate for the management ofCOVID-19. Drug Development Research, 1–7.

* GARDEN (NCT04659109) is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 2 trial evaluating the efficacy and the safety of 1000mg glenzocimab, administered daily over three consecutive days. The Sponsor Acticor Biotech Announced 7.23.21 the Completion of Enrollment in its GARDEN clinical trial. For more information, go to:

Share this: